Share on StockTwits

Stock analysts at RBC Capital raised their price target on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from $425.00 to $500.00 in a report issued on Tuesday. The firm currently has an “outperform” rating on the stock. RBC Capital’s price objective would suggest a potential upside of 110.81% from the company’s current price.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 10,000 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $226.72, for a total value of $2,267,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of other analysts have also recently weighed in on ICPT. Analysts at Leerink Swann upgraded shares of Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday. They now have a $445.00 price target on the stock, up previously from $270.00. Separately, analysts at Deutsche Bank upgraded shares of Intercept Pharmaceuticals to an “outperform” rating in a research note on Tuesday. They now have a $500.00 price target on the stock, up previously from $395.00. Finally, analysts at Nomura upgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 29th. They now have a $323.00 price target on the stock. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $489.70.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 237.18 on Tuesday. Intercept Pharmaceuticals has a one year low of $42.41 and a one year high of $497.00. The stock’s 50-day moving average is $232.5 and its 200-day moving average is $291.8. The company’s market cap is $5.001 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. On average, analysts predict that Intercept Pharmaceuticals will post $-14.82 earnings per share for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.